Update 2020: Management of Non-Small Cell Lung Cancer
- PMID:33175991
- PMCID: PMC7656891
- DOI: 10.1007/s00408-020-00407-5
Update 2020: Management of Non-Small Cell Lung Cancer
Abstract
The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.
Keywords: Immune checkpoint inhibitors; Lung cancer; Targeted therapy.
Conflict of interest statement
Mariam Alexander and So Yeon Kim do not have any conflicts of interest to disclose. Haiying Cheng has received research funding from Genentech/Roche, Eisai, Spectrum, Regeneron, Bayer, and Vaccinex.
Similar articles
- Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.Duma N, Santana-Davila R, Molina JR.Duma N, et al.Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.Mayo Clin Proc. 2019.PMID:31378236Review.
- Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.Genova C, Rossi G, Tagliamento M, Rijavec E, Biello F, Cerbone L, Zullo L, Grossi F.Genova C, et al.Expert Rev Respir Med. 2020 Apr;14(4):367-383. doi: 10.1080/17476348.2020.1714441. Epub 2020 Jan 17.Expert Rev Respir Med. 2020.PMID:31917616Review.
- Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.Li MSC, Mok KKS, Mok TSK.Li MSC, et al.Ann Transl Med. 2023 Aug 30;11(10):358. doi: 10.21037/atm-22-4444. Epub 2023 Mar 23.Ann Transl Med. 2023.PMID:37675321Free PMC article.Review.
- Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.Chen J, Lu W, Chen M, Cai Z, Zhan P, Liu X, Zhu S, Ye M, Lv T, Lv J, Song Y, Wang D.Chen J, et al.Ther Adv Med Oncol. 2024 Feb 27;16:17588359231225036. doi: 10.1177/17588359231225036. eCollection 2024.Ther Adv Med Oncol. 2024.PMID:38420602Free PMC article.Review.
- [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].Oncology Society of Chinese Medical Association; Chinese Medical Association Publishing House.Oncology Society of Chinese Medical Association, et al.Zhonghua Zhong Liu Za Zhi. 2023 Jul 23;45(7):539-574. doi: 10.3760/cma.j.cn112152-20230510-00200.Zhonghua Zhong Liu Za Zhi. 2023.PMID:37460438Chinese.
Cited by
- Evaluating the predictive significance of systemic immune-inflammatory index and tumor markers in lung cancer patients with bone metastases.He J, Liang G, Yu H, Lin C, Shen W.He J, et al.Front Oncol. 2024 Jan 9;13:1338809. doi: 10.3389/fonc.2023.1338809. eCollection 2023.Front Oncol. 2024.PMID:38264753Free PMC article.
- Efficacy and Safety of Autologous Cytokine-Induced Killer (CIK) Cellular Immunotherapy Combined with Chemotherapy in Non-Small-Cell Carcinoma (NSCLC): A Meta-Analysis.Zhong C, Tang H, Wang Q.Zhong C, et al.Iran J Public Health. 2024 Aug;53(8):1722-1735. doi: 10.18502/ijph.v53i8.16277.Iran J Public Health. 2024.PMID:39415869Free PMC article.Review.
- Hesperidin inhibits tobacco smoke-induced pulmonary cell proliferation and EMT in mouse lung tissues via the p38 signaling pathway.Liang Z, Zhang Y, Xu Y, Zhang X, Wang Y.Liang Z, et al.Oncol Lett. 2022 Nov 29;25(1):30. doi: 10.3892/ol.2022.13616. eCollection 2023 Jan.Oncol Lett. 2022.PMID:36589667Free PMC article.
- Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer.Chen D, Zhang H, Zhao L, Liu X, Xue S, Wu P, Jiang H.Chen D, et al.Cell Cycle. 2023 Apr;22(7):841-857. doi: 10.1080/15384101.2022.2159203. Epub 2022 Dec 19.Cell Cycle. 2023.PMID:36536539Free PMC article.
- Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments.Grassi F, Granata V, Fusco R, De Muzio F, Cutolo C, Gabelloni M, Borgheresi A, Danti G, Picone C, Giovagnoni A, Miele V, Gandolfo N, Barile A, Nardone V, Grassi R.Grassi F, et al.J Clin Med. 2023 Feb 10;12(4):1442. doi: 10.3390/jcm12041442.J Clin Med. 2023.PMID:36835977Free PMC article.Review.
References
- de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 'tWesteinde S, Prokop M, Mali WP, Hoesein FAAM, van Ooijen PMA, Aerts J, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced lung-cancer mortality with volume CT screening in a randomized trial. New Engl J Med. 2020;382(6):503–513. doi: 10.1056/NEJMoa1911793. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous